Form 8-K · Current Report · Filed 2026-09-10
DexCom Appoints Glenn Boehnlein to Board of Directors
On September 10, 2026, DexCom, Inc. announced the appointment of Glenn Boehnlein to its Board of Directors, effective immediately. Mr. Boehnlein, a seasoned healthcare executive and former CFO of Stryker Corporation, brings extensive experience in financial leadership, strategic M&A, and operational excellence. He was granted an initial equity grant of restricted stock units (RSUs) with a fair value of $500,000, vesting annually over three years, and will be eligible for an annual equity grant of $347,500 for his service on the Board and committees. This appointment is part of DexCom's strategy to enhance its Board with industry expertise.
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-26-000167
- CIK
- 0001093557
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$83.88
Since filing
+0.0%
Latest close
$83.88
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, DXCM insiders reported 14 Form 4 transactions — net selling of $3.7M.
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.